{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:38:23Z","timestamp":1793907503353,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eclinm.2024.103067","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T10:27:22Z","timestamp":1737541642000},"page":"103067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-5643","authenticated-orcid":false,"given":"Hanneke","family":"van Laarhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Berge Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Haj","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina T.","family":"Muijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Beerepoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grard","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.eclinm.2024.103067_bib1","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.103067_bib2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103067_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/0284186X.2020.1870246","article-title":"Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study","volume":"60","author":"Al-Kaabi","year":"2021","journal-title":"Acta Oncol"},{"issue":"13","key":"10.1016\/j.eclinm.2024.103067_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.103067_bib5","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.annonc.2024.05.350","article-title":"438P Adjuvant nivolumab after neoadjuvant chemoradiotherapy and surgery for patients with esophageal or gastroesophageal junction cancer: a nationwide real-world matched comparison of overall survival","volume":"35","author":"Verhoeven","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.103067_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2024.103067_bib7","series-title":"Prospective Randomized Multicenter Phase III Trial Comparing Perioperative Chemotherapy (FLOT Protocol) to Neoadjuvant Chemoradiation (CROSS Protocol) in Patients with Adenocarcinoma of the Esophagus (ESOPEC Trial)","author":"Hoeppner","year":"2024"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103067_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ejca.2015.03.017","article-title":"Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practice","volume":"51","author":"Srikanthan","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103067_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cncr.35075","article-title":"Efficacy-effectiveness gaps in oncology: looking beyond survival","volume":"130","author":"Wilson","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103067_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071291","article-title":"Perioperative chemotherapy for gastro-esophageal or gastric cancer: anthracyclin triplets versus FLOT","volume":"16","author":"Geerts","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103067_bib11","doi-asserted-by":"crossref","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.103067_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.076","article-title":"LBA75 neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial","volume":"34","author":"Van der Wilk","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103067_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12885-018-4034-1","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial","volume":"18","author":"Noordman","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103067_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-023-10747-z","article-title":"A\u00a0prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of surgery as needed for oesophageal cancer-2","volume":"23","author":"van der Zijden","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.103067_bib15","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103067_bib16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103067_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers13010141","article-title":"Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103067_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.eclinm.2024.103067_bib19","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/bjs\/znac314","article-title":"Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison","volume":"109","author":"Eyck","year":"2022","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103067_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.6004\/jnccn.2024.7014","article-title":"Chemotherapy-induced peripheral neuropathy in patients with gastroesophageal cancer","volume":"22","author":"van Velzen","year":"2024","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.eclinm.2024.103067_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2020.05.038","article-title":"Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines","volume":"150","author":"Mir","year":"2020","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103067_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11864-024-01186-4","article-title":"Harnessing the potential of real-world evidence in the treatment of colorectal cancer: where do we stand?","volume":"25","author":"van Nassau","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103067_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","article-title":"The \u201cefficacy-effectiveness gap\u201d: historical background and current conceptualization","volume":"19","author":"Nordon","year":"2016","journal-title":"Value Health"},{"issue":"15","key":"10.1016\/j.eclinm.2024.103067_bib24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.19.02035","article-title":"Informing patients about expected outcomes: the efficacy-effectiveness gap","volume":"38","author":"Templeton","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103067_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy\u2013effectiveness gap: a regulator's perspective on addressing variability of drug response","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103067_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.19.01814","article-title":"Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study","volume":"38","author":"Stroes","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.eclinm.2024.103067_bib27","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT versus FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2\u2013positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T19:56:48Z","timestamp":1740859008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024006461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":27,"alternative-id":["S2589537024006461"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103067","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103067"}}